coronary artery disease with diabetes, including impaired glucose tolerance
Conditions
Interventions
Acarbose is initiated before each meal with 50mg/time, 3 times/day, and increased to 100mg/time after examining tolerability if there is no enough therapeutic effect. However, the dosage shall be dete
Sponsors
Cardiovascular Center,Anjo Kosei Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who were found at catheterization test to have more than 50 % of stenosis, diagnosed with diabetic (including IGT) at 75g oral glucose tolerance test : 140mg/dl or more, HbA1c : less than 6.5%) are assigned to groups with or without Acarbose for comparison. 1) Subjects who are hyperlipidemic or who require administration of statin
Exclusion criteria
Exclusion criteria: Any subject who applies to the article below shall be excluded. 1) Patients on oral antidiabetic or insulin preparation 2) Patients with a history of ileus or undergone laparotomy 3) Patients with severe liver dysfunction or renal dysfunction 4) Patients with serious case of ketosis or diabetical coma, or precoma 5) Patients with severe infection disease, or in the perioperative period, or with extreme trauma 6) Patients with gastrointestinal problems such as diarrhea, vomiting 7) Patients with a history of sensitivity to Acarbose 8) Pregnant or possibly pregnant women 9) Patients judged by the investigator/subinvestigator to be ineligible for some other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of cardiovascular events: new onset myocardial infarction, worsening anginal status and/or angiographic restenosis Carotid intima-medial thickness(IMT) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-1)Ultrasonic echo cardiography(IVS; Interventricular Septal Thickness, EF; Ejection Fraction, E/A, LVDd; Left Ventricular Diastolic dimension) 2-1)HbA1c 2-2)IRI 2-3)blood glucose levels 2-4)HOMA-R,HOMA-beta 3)Plasma lipid profile | — |
Countries
Japan
Outcome results
None listed